IPP Bureau
Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
By IPP Bureau - October 07, 2022
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
L&T Construction bags order to construct manufacturing facility in Haryana
By IPP Bureau - October 07, 2022
This win is on the back of a prestigious order from Reliance Life Sciences
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
By IPP Bureau - October 07, 2022
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Atul Healthcare to acquire stake in VIMS
By IPP Bureau - October 05, 2022
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Granules India inaugurated water tank at Bonthapally village
By IPP Bureau - October 05, 2022
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
NATCO launches Chlorantraniliprole combination agro products in India
By IPP Bureau - October 05, 2022
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Lupin receives approval from USFDA for Darunavir Tablets
By IPP Bureau - October 05, 2022
The product will be manufactured at Lupin's facility in Nagpur, India.
Casper Pharma receives EIR from USFDA for its PAI
By IPP Bureau - October 05, 2022
The inspection concluded with no observation (FDA-483) issued.
Medcare acquires 60% stake in Skin III
By IPP Bureau - October 05, 2022
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Zydus receives USFDA tentative approval for Amantadine Extended-Release capsules
By IPP Bureau - October 05, 2022
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Wockhardt Hospitals, Mira Road starts a Comprehensive Clinic for Cancer Patients
By IPP Bureau - October 05, 2022
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets
By IPP Bureau - October 04, 2022
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
AGC begins study to expand its Bio-CDMO capability in Japan
By IPP Bureau - October 04, 2022
Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment
By IPP Bureau - October 04, 2022
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Fluor bags award for Biologics manufacturing facility in Scandinavia
By IPP Bureau - October 04, 2022
Construction is now underway with the facility scheduled to be operational by 2025
